| Not Yet Recruiting | NG101m Adjuvant Therapy in Glioblastoma Patients NCT04373785 | NeuGATE Theranostics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform NCT01777919 | Olympion Medical Center | Phase 2 |
| Not Yet Recruiting | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 / Phase 2 |
| Suspended | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma NCT06806228 | Petrov, Andrey | Phase 1 |
| Recruiting | Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] NCT06466031 | Copernicus Memorial Hospital | N/A |
| Recruiting | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Gliobla NCT06991101 | Baptist Health South Florida | Phase 2 |
| Recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496 | University of Arizona | Phase 1 / Phase 2 |
| Withdrawn | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma NCT04482933 | Pediatric Brain Tumor Consortium | Phase 2 |
| Recruiting | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion NCT06333899 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblas NCT06356883 | Université de Sherbrooke | Phase 2 |
| Recruiting | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age NCT05956821 | University of Miami | Phase 1 / Phase 2 |
| Recruiting | Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An NCT06533163 | BioTex, Inc. | N/A |
| Recruiting | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue NCT05756985 | Baptist Health South Florida | — |
| Not Yet Recruiting | The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM NCT06218524 | Southern Medical University, China | Phase 2 |
| Suspended | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma NCT02546102 | Precision Life Sciences Group | Phase 3 |
| Recruiting | A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without NCT06496971 | NaviFUS Corporation | Phase 3 |
| Recruiting | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblast NCT06329570 | NaviFUS Corporation | Phase 1 / Phase 2 |
| Recruiting | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma NCT06585527 | Beijing Neurosurgical Institute | Phase 1 |
| Recruiting | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Targeted Pediatric High-Grade Glioma Therapy NCT05839379 | Nationwide Children's Hospital | — |
| Not Yet Recruiting | A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research NCT05958485 | Power Life Sciences Inc. | — |
| Completed | FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) NCT06451042 | Sunnybrook Health Sciences Centre | — |
| Not Yet Recruiting | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy NCT05500612 | University of Sydney | — |
| Unknown | TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. NCT06353360 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Phase 2 |
| Recruiting | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma NCT06418113 | Hospital San Carlos, Madrid | Phase 1 |
| Recruiting | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma NCT06157541 | Queensland Institute of Medical Research | Phase 1 / Phase 2 |
| Unknown | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas NCT06241391 | All India Institute of Medical Sciences, Bhubaneswar | N/A |
| Recruiting | Sonodynamic Therapy in Patients With Recurrent GBM NCT06039709 | Shayan Moosa, MD | Phase 1 |
| Recruiting | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma NCT05864534 | Northwestern University | Phase 2 |
| Recruiting | NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme NCT06271421 | Poznan University of Medical Sciences | N/A |
| Recruiting | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab NCT06011109 | Aveta Biomics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning NCT05864976 | Washington University School of Medicine | — |
| Recruiting | A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma NCT06016452 | Tata Memorial Centre | Phase 2 |
| Terminated | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. NCT05977322 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients NCT06054529 | AdventHealth Translational Research Institute | — |
| Recruiting | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Meas NCT06059690 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Enrolling By Invitation | Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme NCT05908669 | University of Aarhus | — |
| Not Yet Recruiting | New Antigens Against Glioblastoma NCT05917821 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma NCT05353530 | University of Florida | Phase 1 |
| Recruiting | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367 | Orbus Therapeutics, Inc. | Phase 1 |
| Suspended | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumo NCT05934630 | Pediatric Brain Tumor Consortium | — |
| Recruiting | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma NCT05954858 | Northwell Health | N/A |
| Recruiting | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in NCT05708352 | Cedars-Sinai Medical Center | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Active Not Recruiting | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma NCT05561374 | Oblato, Inc. | Phase 1 |
| Recruiting | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) NCT05979064 | Northwell Health | N/A |
| Recruiting | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) NCT05450744 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Active Not Recruiting | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM NCT03862430 | NuvOx LLC | Phase 2 |
| Not Yet Recruiting | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma NCT05095441 | ImmVira Pharma Co. Ltd | Phase 1 |
| Active Not Recruiting | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Gl NCT04900792 | Bryan Allen | Phase 1 |
| Completed | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients NCT04845919 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 2 |
| Recruiting | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) NCT05052957 | Leland Metheny | Phase 2 |
| Recruiting | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) NCT06146738 | Jasper Gerritsen | — |
| Recruiting | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) NCT06283927 | Jasper Gerritsen | — |
| Recruiting | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) NCT06146725 | Jasper Gerritsen | — |
| Recruiting | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. NCT05686798 | Henry Ford Health System | Phase 1 |
| Recruiting | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent NCT05769660 | BeyondBio Inc. | Phase 1 |
| Completed | Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based NCT06346821 | Sichuan University | — |
| Unknown | Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning NCT05624736 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Recruiting | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme NCT05423210 | Stony Brook University | EARLY_Phase 1 |
| Unknown | Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme NCT05589961 | The Second Hospital of Hebei Medical University | EARLY_Phase 1 |
| Recruiting | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc NCT05366179 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Response Assessment During MR-guided Radiation Therapy for Glioblastoma NCT05565326 | University of Zurich | — |
| Recruiting | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Gli NCT05083754 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) NCT04752813 | BPGbio | Phase 2 |
| Recruiting | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recur NCT05303467 | Boston Scientific Corporation | Phase 1 |
| Recruiting | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients NCT04765514 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid NCT05495295 | Phost'In Therapeutics | Phase 1 |
| Active Not Recruiting | Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) NCT05120284 | University of Florida | Phase 2 |
| Active Not Recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma an NCT04978727 | Children's Oncology Group | Phase 1 |
| Completed | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma NCT05432375 | Mundipharma Research Limited | EARLY_Phase 1 |
| Withdrawn | Multimodality MRI and Liquid Biopsy in GBM NCT04776980 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Active Not Recruiting | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients NCT05182905 | Nader Sanai | EARLY_Phase 1 |
| Terminated | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial NCT04825275 | Milton S. Hershey Medical Center | EARLY_Phase 1 |
| Terminated | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas NCT04869449 | Milton S. Hershey Medical Center | EARLY_Phase 1 |
| Recruiting | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation NCT05271240 | Northwell Health | Phase 3 |
| Unknown | PreOperative Brain Irradiation in Glioblastoma NCT03582514 | The Christie NHS Foundation Trust | Phase 1 |
| Recruiting | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma NCT05281731 | Washington University School of Medicine | N/A |
| Withdrawn | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type NCT05218408 | Celularity Incorporated | Phase 1 / Phase 2 |
| Recruiting | Study of Pembrolizumab and M032 (NSC 733972) NCT05084430 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) NCT05222802 | Katmai Pharmaceuticals Inc. | Phase 1 |
| Completed | Chlorpromazine and Standard of Care in Glioblastoma NCT05190315 | Mohammed Milhem | Phase 1 |
| Recruiting | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients NCT04765098 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma NCT04977375 | Chirag G. Patil | Phase 1 / Phase 2 |
| Active Not Recruiting | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma NCT05076513 | Nader Sanai | EARLY_Phase 1 |
| Completed | IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study NCT05402241 | University of Manitoba | — |
| Terminated | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. NCT04712721 | Novartis Pharmaceuticals | EARLY_Phase 1 |
| Active Not Recruiting | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma NCT05023551 | Sumitomo Pharma America, Inc. | EARLY_Phase 1 |
| Unknown | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) NCT04874506 | Matrix Biomed, Inc. | Phase 2 |
| Completed | UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial NCT04726397 | Sunnybrook Health Sciences Centre | N/A |
| Terminated | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection NCT04608812 | OncoSynergy, Inc. | Phase 1 |
| Completed | BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and NCT05375318 | Juan M Garcia-Gomez | — |
| Active Not Recruiting | Surgical Nivolumab And Ipilimumab For Recurrent GBM NCT04606316 | Patrick Wen, MD | Phase 1 |
| Active Not Recruiting | Study of Pamiparib in Newly Diagnosed and rGBM NCT04614909 | Nader Sanai | EARLY_Phase 1 |
| Unknown | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine NCT04671459 | Prof. Franciszek Lukaszczyk Memorial Oncology Center | Phase 2 |
| Completed | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Tre NCT04471844 | NovoCure Ltd. | N/A |
| Completed | 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET) NCT05608395 | Masaryk Memorial Cancer Institute | Phase 2 |
| Unknown | Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma NCT04530006 | CancerCare Manitoba | N/A |
| Unknown | Trial of AEO in New Glioblastoma (GBM) NCT04450160 | MetVital, Inc. | Phase 2 |
| Active Not Recruiting | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Gliobl NCT04528680 | Northwestern University | Phase 1 / Phase 2 |
| Terminated | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420 | Celularity Incorporated | Phase 1 |
| Completed | Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS NCT04810182 | Istituto Oncologico Veneto IRCCS | — |
| Withdrawn | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Ci NCT03980249 | West Virginia University | EARLY_Phase 1 |
| Completed | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas NCT04295759 | Pediatric Brain Tumor Consortium | Phase 1 |
| Completed | Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients NCT04446416 | NaviFUS Corporation | N/A |
| Completed | Evaluation of GLR2007 for Advanced Solid Tumors NCT04444427 | Gan and Lee Pharmaceuticals, USA | Phase 1 / Phase 2 |
| Completed | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM NCT04492163 | NovoCure GmbH | Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Terminated | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastom NCT04421378 | Karyopharm Therapeutics Inc | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Lepto NCT05063682 | Chembrain LTD | Phase 1 |
| Unknown | Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM NCT04284306 | Assiut University | — |
| Active Not Recruiting | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM NCT03961971 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Unknown | Vacuolar ATPase and Drug Resistance of High Grade Gliomas NCT05328089 | University of Milano Bicocca | — |
| Unknown | 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme NCT04588454 | Radboud University Medical Center | N/A |
| Suspended | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recu NCT04222309 | Northwell Health | Phase 1 |
| Unknown | Repurposing Chlorpromazine in the Treatment of Glioblastoma NCT04224441 | Marco G Paggi, MD, PhD | Phase 2 |
| Terminated | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM NCT03705351 | Providence Health & Services | Phase 1 |
| Active Not Recruiting | LAM561 With RT and TMZ for Adults With Glioblastoma NCT04250922 | Laminar Pharmaceuticals | Phase 2 / Phase 3 |
| Unknown | ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) NCT04277221 | Safe Save Medical Cell Sciences & Technology Co.,Ltd. | Phase 3 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients NCT04116411 | Cecilia Soderberg-Naucler | Phase 2 |
| Terminated | Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells NCT03861598 | West Virginia University | EARLY_Phase 1 |
| Withdrawn | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma NCT03506139 | John M. Buatti | Phase 2 |
| Unknown | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer NCT03916757 | Immunitor LLC | Phase 2 |
| Completed | 131I-IPA and Concurrent XRT in Recurrent GBM NCT03849105 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 / Phase 2 |
| Recruiting | The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. NCT03861299 | Jasper Gerritsen | N/A |
| Terminated | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblast NCT03707457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Completed | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients NCT03865355 | Novosibirsk State University | — |
| Active Not Recruiting | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT NCT03866109 | Genenta Science | Phase 1 / Phase 2 |
| Completed | A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade G NCT03834740 | St. Joseph's Hospital and Medical Center, Phoenix | EARLY_Phase 1 |
| Unknown | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Mali NCT03607643 | Leaf Vertical Inc. | Phase 1 / Phase 2 |
| Completed | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma NCT03027388 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Glycemic Impact on Glioblastoma Outcomes NCT03235934 | University Health Network, Toronto | — |
| Unknown | MRI Predictors of Response to Tumor Treating Fields NCT03642080 | New York Presbyterian Brooklyn Methodist Hospital | — |
| Completed | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma NCT03665545 | University Hospital, Geneva | Phase 1 / Phase 2 |
| Unknown | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme NCT03025893 | Amsterdam UMC, location VUmc | Phase 2 / Phase 3 |
| Completed | ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy NCT03712293 | InSightec | N/A |
| Completed | Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients NCT03626896 | NaviFUS Corporation | N/A |
| Active Not Recruiting | A Trial of Ipatasertib in Combination With Atezolizumab NCT03673787 | Institute of Cancer Research, United Kingdom | Phase 1 / Phase 2 |
| Completed | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Gli NCT06562621 | Beijing Neurosurgical Institute | Phase 1 / Phase 2 |
| Terminated | UNITE Study: Understanding New Interventions With GBM ThErapy NCT03419403 | AbbVie | Phase 3 |
| Active Not Recruiting | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM NCT03630289 | Northwell Health | N/A |
| Recruiting | IA Carboplatin + Radiotherapy in Relapsing GBM NCT03672721 | Université de Sherbrooke | Phase 1 / Phase 2 |
| Unknown | 3D Prediction of Patient-Specific Response NCT03561207 | KIYATEC | — |
| Terminated | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme NCT03363659 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Phase I EGFR BATs in Newly Diagnosed Glioblastoma NCT03344250 | University of Virginia | Phase 1 |
| Active Not Recruiting | Phase I Study of APX005M in Pediatric Central Nervous System Tumors NCT03389802 | Pediatric Brain Tumor Consortium | Phase 1 |
| Active Not Recruiting | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM NCT04195139 | University of Sydney | Phase 2 |
| Unknown | Multi-site Validation and Application of a Consensus DSC-MRI Protocol NCT03401866 | St. Joseph's Hospital and Medical Center, Phoenix | N/A |
| Completed | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Express NCT03050736 | Kintara Therapeutics, Inc. | Phase 2 |
| Recruiting | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM NCT03596086 | David Baskin MD | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Su NCT03382977 | VBI Vaccines Inc. | Phase 1 / Phase 2 |
| Terminated | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma NCT03119064 | Brown University | Phase 1 / Phase 2 |
| Recruiting | Loupe-Based Intraoperative Fluorescence Imaging NCT04780009 | Guoqiang Yu | — |
| Completed | Nativis Voyager for Newly Diagnosed GBM NCT03276286 | Nativis, Inc. | N/A |
| Terminated | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM NCT03149575 | DelMar Pharmaceuticals, Inc. | Phase 3 |
| Completed | 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme NCT03291990 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Terminated | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 NCT03332355 | Vanquish Oncology, Inc. | Phase 1 |
| Recruiting | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid NCT03175224 | Apollomics Inc. | Phase 2 |
| Recruiting | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma NCT02704858 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 NCT03152318 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Hypofractionated Radiation Therapy for Glioblastoma NCT03212235 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Terminated | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children NCT02885324 | Indiana University | Phase 2 |
| Unknown | TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM NCT03780569 | NovoCure Ltd. | N/A |
| Completed | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma NCT03072134 | Northwestern University | Phase 1 |
| Completed | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma NCT02858895 | Medicenna Therapeutics, Inc. | Phase 2 |
| Completed | Ketogenic Diets as an Adjuvant Therapy in Glioblastoma NCT03075514 | University of Liverpool | N/A |
| Active Not Recruiting | A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme NCT02344355 | Bryan Allen | Phase 2 |
| Completed | FET-PET Directed Simultaneous In-field Boost for Primary GBM NCT04790097 | Prof. Franciszek Lukaszczyk Memorial Oncology Center | N/A |
| Completed | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurre NCT02717962 | Kintara Therapeutics, Inc. | Phase 2 |
| Unknown | uPAR-PET/MRI in Glioblastoma Multiforme NCT02945826 | Rigshospitalet, Denmark | Phase 2 |
| Unknown | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme NCT03347097 | Huashan Hospital | EARLY_Phase 1 |
| Completed | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme NCT02619864 | Canadian Cancer Trials Group | Phase 1 |
| Terminated | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma NCT02663271 | University of Florida | Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens NCT02864368 | Eric Thompson, M.D. | Phase 1 |
| Unknown | FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy NCT03370926 | University Hospital, Brest | — |
| Active Not Recruiting | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients NCT02933736 | Nader Sanai | EARLY_Phase 1 |
| Unknown | Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study NCT02939378 | Song Lin | Phase 1 / Phase 2 |
| Completed | Temozolomide Chronotherapy for High Grade Glioma NCT02781792 | Washington University School of Medicine | Phase 2 |
| Completed | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme NCT02465268 | University of Florida | Phase 2 |
| Completed | A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme NCT02853565 | CANbridge Life Sciences Ltd. | Phase 1 |
| Completed | The Addition of Chloroquine to Chemoradiation for Glioblastoma NCT02378532 | Maastricht Radiation Oncology | Phase 1 |
| Unknown | Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme NCT02844062 | Beijing Sanbo Brain Hospital | Phase 1 |
| Unknown | Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme NCT02937844 | Beijing Sanbo Brain Hospital | Phase 1 |
| Unknown | Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients NCT02815410 | Seoul National University Hospital | Phase 2 |
| Terminated | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine NCT02722512 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 |
| Completed | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT02709226 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblas NCT02715609 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Terminated | Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma NCT02769806 | University of Wisconsin, Madison | — |
| Completed | Determination of Immune Phenotype in Glioblastoma Patients NCT02751138 | University of Ulm | — |
| Completed | Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. NCT04610229 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Active Not Recruiting | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM NCT02586857 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Unknown | Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage C NCT02663440 | Zhejiang Cancer Hospital | Phase 2 |
| Completed | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) NCT01931098 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma NCT02510950 | Washington University School of Medicine | Phase 1 |
| Completed | Cancer Stem Cell High-Throughput Drug Screening Study NCT02654964 | Swedish Medical Center | Phase 1 |
| Terminated | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma NCT02414165 | Tocagen Inc. | Phase 2 / Phase 3 |
| Completed | Regorafenib in Relapsed Glioblastoma NCT02926222 | Istituto Oncologico Veneto IRCCS | Phase 2 |
| Completed | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies NCT02498665 | Sumitomo Pharma America, Inc. | Phase 1 |
| Completed | DC Migration Study for Newly-Diagnosed GBM NCT02366728 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Phase 2 |
| Completed | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primar NCT02502708 | NewLink Genetics Corporation | Phase 1 |
| Completed | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme NCT02386826 | SCRI Development Innovations, LLC | Phase 1 |
| Completed | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma NCT02590263 | AbbVie | Phase 1 / Phase 2 |
| Completed | A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in NCT02507102 | Nativis, Inc. | N/A |
| Unknown | Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents. NCT03225963 | Taichung Veterans General Hospital | — |
| Terminated | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma NCT02850744 | PIQUR Therapeutics AG | Phase 2 |
| Completed | Neoadjuvant Nivolumab in Glioblastoma NCT02550249 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Recruiting | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme NCT02331498 | Centre Antoine Lacassagne | Phase 1 / Phase 2 |
| Completed | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma NCT02026271 | Alaunos Therapeutics | Phase 1 |
| Withdrawn | Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme NCT01317212 | North Bristol NHS Trust | Phase 1 |
| Withdrawn | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma NCT02540135 | University of Colorado, Denver | N/A |
| Active Not Recruiting | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients W NCT02780024 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 |
| Terminated | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely NCT02365662 | AbbVie | Phase 1 |
| Completed | Evaluating Therapeutic Response to Novo-TTF NCT02441322 | Abramson Cancer Center at Penn Medicine | N/A |
| Completed | Glioma Modified Atkins-based Diet in Patients With Glioblastoma NCT02286167 | Wake Forest University Health Sciences | N/A |
| Terminated | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-0 NCT02296476 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies NCT02223052 | Celgene | Phase 1 |
| Active Not Recruiting | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme NCT02177578 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme NCT02285959 | Global Neurosciences Institute | Phase 1 |
| Completed | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multi NCT02078648 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma NCT02176720 | The Methodist Hospital Research Institute | Phase 1 |
| Completed | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma NCT02189109 | NuvOx LLC | Phase 1 |
| Completed | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme NCT02120287 | Ajay Niranjan | Phase 2 |
| Completed | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma NCT01811992 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomus NCT01562197 | Bart Neyns | Phase 2 |
| Completed | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study NCT02104882 | Universitätsmedizin Mannheim | Phase 1 / Phase 2 |
| Completed | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors NCT02052648 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Completed | Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme NCT02017249 | Inova Health Care Services | Phase 1 |
| Completed | A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) NCT02296580 | Nativis, Inc. | N/A |
| Completed | Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastom NCT02067156 | GenSpera, Inc. | Phase 2 |
| Terminated | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/ NCT02060955 | CytoVac A/S | Phase 2 |
| Completed | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brai NCT01985256 | Tocagen Inc. | Phase 1 |
| Completed | Phase I Study of Safety and Immunogenicity of ADU-623 NCT01967758 | Providence Health & Services | Phase 1 |
| Completed | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma NCT02010606 | Cedars-Sinai Medical Center | Phase 1 |
| Completed | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma NCT02029573 | King Fahad Medical City | Phase 2 |
| Terminated | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avast NCT02047214 | Cortice Biosciences, Inc. | Phase 2 |
| Completed | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma NCT02049489 | Precision Life Sciences Group | Phase 1 |
| Completed | Immunophenotyping From Blood of Patients With Malignant Gliomas NCT02022384 | University of Erlangen-Nürnberg Medical School | — |
| Completed | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas NCT01837862 | Julie Krystal | Phase 1 / Phase 2 |
| Completed | CT Perfusion in the Prognostication of Cerebral High Grade Glioma NCT01923922 | Nova Scotia Health Authority | N/A |
| Terminated | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors NCT01902771 | Edward Ziga | Phase 1 |
| Completed | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma NCT01956734 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 1 |
| Completed | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma NCT01808820 | Macarena De La Fuente, MD | Phase 1 |
| Completed | Engagement of Patients With Advanced Cancer NCT02966509 | Stanford University | N/A |
| Suspended | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Gliobla NCT01933815 | Cortice Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma M NCT01873469 | Technische Universität Dresden | — |
| Terminated | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Unde NCT01884740 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Completed | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) NCT01856933 | Heinrich Elinzano, MD | Phase 2 |
| Completed | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme NCT01800695 | AbbVie | Phase 1 |
| Completed | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme NCT01752491 | Joseph J. Cullen, MD, FACS | Phase 1 |
| Completed | An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Re NCT01618747 | Hoffmann-La Roche | — |
| Withdrawn | Re-irradiation of High Grade Gliomas: a Quality of Life Study NCT01711580 | Maastricht Radiation Oncology | — |
| Completed | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagn NCT01811498 | Northwell Health | Phase 1 / Phase 2 |
| Completed | FET-PET for Evaluation of Response of Recurrent GBM to Avastin NCT01756352 | Marcelo F. Di Carli, MD, FACC | Phase 2 |
| Completed | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study NCT01865162 | Mid-Atlantic Epilepsy and Sleep Center, LLC | Phase 1 |
| Completed | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer NCT01631552 | Gilead Sciences | Phase 1 / Phase 2 |
| Terminated | TRC105 for Recurrent Glioblastoma NCT01778530 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma NCT02928575 | Bassam Abdulkarim | Phase 2 |
| Terminated | NOA-12: BIBF1120 and R-RT in Glioblastoma NCT01666600 | Prof. Dr. Wolfgang Wick | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat NCT01587144 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma NCT01564914 | Tracon Pharmaceuticals Inc. | Phase 2 |
| Completed | PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analog NCT01540513 | University of Wisconsin, Madison | N/A |
| Unknown | Study of DC Vaccination Against Glioblastoma NCT01567202 | Huashan Hospital | Phase 2 |
| Completed | AMG 595 First-in-Human in Recurrent Gliomas NCT01475006 | Amgen | Phase 1 |
| Completed | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Re NCT01470794 | Tocagen Inc. | Phase 1 |
| Completed | Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide NCT01478854 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme NCT01435395 | Emory University | Phase 1 |
| Completed | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multifor NCT01349660 | SCRI Development Innovations, LLC | Phase 1 / Phase 2 |
| Completed | BG & TMZ Therapy of Glioblastoma Multiforme NCT01269424 | Stanton Gerson MD | Phase 1 |
| Completed | A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma NCT01474239 | Hoffmann-La Roche | Phase 2 |
| Completed | AZD7451 for Recurrent Gliomas NCT01468324 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Lomustine for Recurrent GBM NCT01290939 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Terminated | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurr NCT01526837 | Brain & Spine Surgeons of New York | Phase 1 |
| Completed | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma NCT01478178 | Kintara Therapeutics, Inc. | Phase 1 / Phase 2 |
| Suspended | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Rela NCT01386710 | Northwell Health | Phase 1 / Phase 2 |
| Completed | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation NCT01402063 | Brown University | Phase 2 |
| Completed | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. NCT01301430 | Oryx GmbH & Co. KG | Phase 1 / Phase 2 |
| Completed | A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Pa NCT01588769 | CytoVac A/S | Phase 1 |
| Completed | Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors NCT01929720 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients NCT01508117 | University of Cincinnati | Phase 2 |
| Completed | Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors NCT02006563 | University of Miami | — |
| Completed | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma NCT01290692 | TVAX Biomedical | Phase 2 |
| Terminated | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) NCT01110876 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors NCT01351519 | MultiCare Health System Research Institute | Phase 2 |
| Completed | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Rec NCT01308684 | Hoffmann-La Roche | Phase 1 |
| Completed | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologi NCT01353625 | Celgene | Phase 1 |
| Terminated | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) NCT01186406 | Duke University | Phase 2 |
| Completed | AZD8055 for Adults With Recurrent Gliomas NCT01316809 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Vitamin D for Treatment of Glioblastoma Multiforme NCT01181193 | Soroka University Medical Center | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4 NCT01294735 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 NCT04327011 | Tocagen Inc. | Phase 1 |
| Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas NCT01281982 | National Cancer Institute (NCI) | — |
| Completed | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) NCT01280552 | Precision Life Sciences Group | Phase 2 |
| Completed | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme NCT01268566 | MedImmune LLC | Phase 2 |
| Completed | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme NCT01260506 | Vascular Biogenics Ltd. operating as VBL Therapeutics | Phase 1 / Phase 2 |
| Completed | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme NCT01285414 | Myrexis Inc. | Phase 2 |
| Completed | Amgen 386 for Recurrent Glioblastoma NCT01290263 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme NCT01205334 | Baylor College of Medicine | Phase 1 / Phase 2 |